Pfizer (NYSE:PFE) Shares Up 1.7% – What’s Next?

Pfizer Inc. (NYSE:PFE) shares rose 1.7% on Friday . The stock traded as high as $27.13 and last traded at $27.07. Approximately 52,753,648 shares changed hands during mid-day trading, an increase of 11% from the average daily volume of 47,559,922 shares. The stock had previously closed at $26.61.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Analysts Set New Price Targets

Several analysts have recently commented on the stock. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. UBS Group began coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Citigroup assumed coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective on the stock. Finally, Morgan Stanley decreased their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $28.05.

Pfizer Trading Up 1.7%

The stock has a market capitalization of $153.93 billion, a P/E ratio of 19.90 and a beta of 0.47. The stock’s fifty day moving average price is $26.26 and its two-hundred day moving average price is $25.46. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently made changes to their positions in the company. Union Savings Bank purchased a new position in Pfizer during the fourth quarter valued at $296,000. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Pfizer during the fourth quarter valued at $50,000. Mengis Capital Management Inc. raised its position in shares of Pfizer by 12.3% in the 4th quarter. Mengis Capital Management Inc. now owns 64,213 shares of the biopharmaceutical company’s stock worth $1,599,000 after purchasing an additional 7,056 shares during the last quarter. Bayban bought a new position in Pfizer in the 4th quarter worth about $114,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Pfizer in the 4th quarter worth about $2,555,000. 68.36% of the stock is currently owned by institutional investors.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.